IRCM Activities
and Events


Events to come

Feb 26, 2024
From 11:30 AM to 12:30 PM

Location QCCanada
IRCM Conference

Jean-Sébastien Delisle

Jean-Sébastien Delisle

Translating T-cell biology into cellular therapies

Jean-Sébastien Delisle, MD, PhD
Associate Professor
Department of Medecine
Université de Montréal
Maisonneuve-Rosemont Hospital Research Centre

This conference is hosted by Nabil G. Seidah, PhD. This conference is part of the 2023-2024 IRCM conference calendar.

In person: 
IRCM Auditorium
110, avenue des Pins O, H2W 1R7 Montreal

About this conference
The combined advances in cellular processing/engineering and in our understanding of T-cell biology has led to revolutionary cell-based immunotherapies. The current cellular immunotherapies remain nonetheless limited by the constraints imposed by T-cell biology, ranging from antigenic recognition to the development of T-cell dysfunction. Based on early-phase clinical trial translational experience and using relevant human T-cell models inspired by clinically-compliant T-cell manufacturing systems, we have characterized how T-cell exhaustion and senescence develop in therapeutic T cells and devised approaches to improve T-cell function using cytokine signaling modulation, inhibitory co-signaling blockade and genetic engineering.

About Jean-Sébastien Delisle
    Dr. Delisle studies the aspects of T-cell biology that are most relevant to adoptive immunotherapy in humans. He leads a research program on basic and translational T-cell biology at Hôpital Maisonneuve-Rosemont and acts as Medical Director of the Centre d’excellence en thérapie cellulaire (CETC), a good-manufacturing procedure (GMP) compliant facility enabling cellular product manufacturing for clinical use. Dr. Delisle contributed to the development and implementation of several protocols used in early-phase clinical trials. Current research interests are focused on the modulation of signals that program T-cell differentiation through multiple approaches including genetic engineering in order to maximize the efficacy of adoptive immunotherapies, as well as immunomonitoring. Dr. Delisle is an FRQS-recognized clinician-scientist and a professor at the Université de Montréal.

To make sure you don't miss any of the IRCM conferences, sign up now for our newsletter!


events and more


IRCM Foundation

Be part of the

Support health research